AU2002343063B2 - Assay for screening candidate drugs for the treatment of inflammatory diseases - Google Patents

Assay for screening candidate drugs for the treatment of inflammatory diseases Download PDF

Info

Publication number
AU2002343063B2
AU2002343063B2 AU2002343063A AU2002343063A AU2002343063B2 AU 2002343063 B2 AU2002343063 B2 AU 2002343063B2 AU 2002343063 A AU2002343063 A AU 2002343063A AU 2002343063 A AU2002343063 A AU 2002343063A AU 2002343063 B2 AU2002343063 B2 AU 2002343063B2
Authority
AU
Australia
Prior art keywords
thetaiotaomicron
inflammatory
cells
composition
enteritidis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2002343063A
Other languages
English (en)
Other versions
AU2002343063A1 (en
Inventor
Denise Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
4D Pharma Research Ltd
Original Assignee
4D Pharma Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4D Pharma Research Ltd filed Critical 4D Pharma Research Ltd
Publication of AU2002343063A1 publication Critical patent/AU2002343063A1/en
Application granted granted Critical
Publication of AU2002343063B2 publication Critical patent/AU2002343063B2/en
Assigned to THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN reassignment THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN Request for Assignment Assignors: ROWETT RESEARCH INSTITUTE
Assigned to GT BIOLOGICS LIMITED reassignment GT BIOLOGICS LIMITED Request for Assignment Assignors: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN
Assigned to 4D PHARMA RESEARCH LIMITED reassignment 4D PHARMA RESEARCH LIMITED Request to Amend Deed and Register Assignors: GT BIOLOGICS LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
AU2002343063A 2001-11-21 2002-11-20 Assay for screening candidate drugs for the treatment of inflammatory diseases Expired AU2002343063B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0127916.5 2001-11-21
GBGB0127916.5A GB0127916D0 (en) 2001-11-21 2001-11-21 Method
PCT/GB2002/005255 WO2003046580A1 (en) 2001-11-21 2002-11-20 Assay for screening candidate drugs for the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
AU2002343063A1 AU2002343063A1 (en) 2003-06-10
AU2002343063B2 true AU2002343063B2 (en) 2008-06-05

Family

ID=9926193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002343063A Expired AU2002343063B2 (en) 2001-11-21 2002-11-20 Assay for screening candidate drugs for the treatment of inflammatory diseases

Country Status (11)

Country Link
US (1) US7998474B2 (da)
EP (1) EP1448995B9 (da)
JP (2) JP5362940B2 (da)
AT (1) ATE496302T1 (da)
AU (1) AU2002343063B2 (da)
CA (1) CA2468082C (da)
DE (1) DE60239009D1 (da)
DK (1) DK1448995T3 (da)
ES (1) ES2362494T3 (da)
GB (1) GB0127916D0 (da)
WO (1) WO2003046580A1 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20050389A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
ITRM20050390A1 (it) * 2005-07-22 2007-01-23 Giuliani Spa Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico.
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
AU2008317000B2 (en) * 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
UA107562C2 (uk) 2008-12-05 2015-01-26 Спосіб лікування псоріазу
EP2396082B1 (en) 2009-02-16 2013-07-31 Nogra Pharma Limited Methods for treating hair related conditions
US20140128276A1 (en) * 2011-01-13 2014-05-08 Oklahoma Medical Research Foundation Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
US20130022575A1 (en) * 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora
GB201117313D0 (en) * 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR20140082964A (ko) 2011-10-11 2014-07-03 아힘 바이오테라퓨틱스 에이비 혐기성 조건으로 배양된 인간 장내 미생물을 포함하는 조성물
EP2811993B1 (en) 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
CN109172816A (zh) 2012-03-29 2019-01-11 塞拉拜姆有限责任公司 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂
NZ631049A (en) 2012-04-18 2017-02-24 Nogra Pharma Ltd Methods of treating lactose intolerance
WO2013188529A1 (en) 2012-06-15 2013-12-19 Temple University Of The Commonwealth System Of Higher Education Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium
CN105120847B (zh) 2013-03-14 2018-12-28 塞拉拜姆有限责任公司 益生生物和/或治疗剂的靶向胃肠道递送
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CN104546935A (zh) * 2014-09-30 2015-04-29 深圳华大基因科技有限公司 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
AU2018205072B2 (en) * 2014-12-23 2020-05-21 Cj Bioscience, Inc. Immune modulation
EA035925B1 (ru) 2014-12-23 2020-09-01 4Д Фарма Рисерч Лимитед Полипептид и иммуномодуляция
EP3065748B1 (en) 2014-12-23 2017-11-22 4D Pharma Research Limited A bacteroides thetaiotaomicron strain and its use in reducing inflammation
FR3035329A1 (fr) * 2015-04-23 2016-10-28 Agronomique Inst Nat Rech La prevention ou le traitement d'une infection par bacteroides thetaiotaomicron
MD3240554T2 (ro) 2015-06-15 2020-01-31 4D Pharma Res Ltd Blautia stercosis și wexlerae pentru utilizare în tratarea bolilor inflamatorii și autoimune
CA2988693A1 (en) 2015-06-15 2016-12-22 4D Pharma Research Limited Compositions comprising bacterial strains
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6439037B2 (ja) 2015-06-15 2018-12-19 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2017029992A1 (ja) * 2015-08-17 2017-02-23 積水メディカル株式会社 免疫学的検出方法及びこれに用いるテストストリップ
RS57138B1 (sr) 2015-11-20 2018-07-31 4D Pharma Res Ltd Kompozicije koje sadrže bakterijske sojeve
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
BR112018067689A2 (pt) 2016-03-04 2019-01-08 4D Pharma Plc composições compreendendo cepas bacterianas do gênero blautia para tratar a hipersensibilidade visceral
TWI750342B (zh) * 2016-06-15 2021-12-21 英商4D製藥研究有限公司 包含菌株之組合物及其用途、製法及產品
TWI782800B (zh) * 2016-06-15 2022-11-01 英商4D製藥研究有限公司 包含菌株之組合物及其用途、製法及產品
TWI621708B (zh) * 2016-06-15 2018-04-21 ４Ｄ製藥研究有限公司 免疫調節
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
MA48941A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
DK3600363T3 (da) 2017-06-14 2021-01-25 4D Pharma Res Ltd Sammensætninger omfattende bakteriestammer
RS60910B1 (sr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Kompozicije koje sadrže bakterijski soj roda megasphaera i njihove upotrebe
LT3638271T (lt) 2017-06-14 2021-01-11 4D Pharma Research Limited Kompozicijos, apimančios bakterines padermes
CA3088343A1 (en) 2018-01-19 2019-07-25 4D Pharma Research Limited Combination therapy for treating or preventing cancer
JP2021516216A (ja) 2018-01-19 2021-07-01 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ がんを処置または予防するための併用療法
CN111629740A (zh) 2018-01-19 2020-09-04 4D制药研究有限公司 用于治疗或预防癌症的组合疗法
AU2019210004A1 (en) 2018-01-19 2020-08-13 4D Pharma Research Limited Combination therapy for treating or preventing cancer
JP2021518414A (ja) 2018-03-19 2021-08-02 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
BR112020022833A2 (pt) 2018-05-11 2021-02-02 4D Pharma Research Limited composições compreendendo cepas bacterianas
JP2021526526A (ja) 2018-06-14 2021-10-07 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
CA3103064A1 (en) 2018-06-19 2019-12-26 4D Pharma Research Ltd Dosage form comprising a live biotherapeutic product
JP6987259B2 (ja) 2018-06-25 2021-12-22 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
KR20210032426A (ko) 2018-07-16 2021-03-24 4디 파마 리서치 리미티드 박테리아 균주를 포함하는 조성물
TW202023590A (zh) 2018-08-17 2020-07-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
JP2022501363A (ja) 2018-09-20 2022-01-06 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
EP3863653A1 (en) * 2018-10-09 2021-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
EP3866822A1 (en) 2018-10-19 2021-08-25 4D Pharma Research Limited Compositions comprising bacterial strains
AU2019373731A1 (en) 2018-11-02 2021-05-27 4D Pharma Research Limited Compositions comprising bacterial strains
EP3876964A1 (en) 2018-12-12 2021-09-15 4D Pharma Research Limited Compositions comprising parabacteroides bacterial strains for treating cancer
KR20210102927A (ko) 2018-12-12 2021-08-20 4디 파마 리서치 리미티드 박테리아 균주를 포함하는 조성물
TW202038977A (zh) 2018-12-12 2020-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
US11905232B2 (en) 2019-02-08 2024-02-20 Nogra Pharma Limited Process of making 3-(4′-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof
BR112021022501A2 (pt) 2019-05-10 2021-12-28 4D Pharma Res Limited Composições compreendendo cepas bacterianas
CA3145904A1 (en) 2019-07-05 2021-01-14 4D Pharma Research Limited Compositions comprising bacterial strains
EP4061389A1 (en) 2019-11-20 2022-09-28 4D Pharma Research Limited Compositions comprising bacterial strains
EP3839039A1 (en) 2019-12-16 2021-06-23 4D Pharma Research Limited Providing bacterial biomass with improved storage stability
EP3838281A1 (en) 2019-12-20 2021-06-23 4D Pharma Research Limited Compositions comprising bacterial strains
TW202140773A (zh) 2020-01-27 2021-11-01 英商4D製藥研究有限公司 包含細菌菌株之組成物
TW202220639A (zh) 2020-08-06 2022-06-01 英商４Ｄ製藥有限公司 凍乾方法
KR20230112700A (ko) 2020-11-26 2023-07-27 4디 파마 레온, 에스.엘.유. 방법
JPWO2022191182A1 (da) * 2021-03-08 2022-09-15
AU2022391025A1 (en) * 2021-11-19 2024-06-06 The Brigham And Women's Hospital, Inc. Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
WO1998057631A1 (en) * 1997-06-18 1998-12-23 The General Hospital Corporation USE OF PPARη AGONISTS FOR INHIBITION OF INFLAMMATORY CYTOKINE PRODUCTION
WO2001016120A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443826A (en) * 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5039703A (en) * 1989-11-16 1991-08-13 Breuer Richard I Method for treating inflammatory bowel disorders
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
GB9616047D0 (en) 1996-07-31 1996-09-11 Glaxo Group Ltd Medicament carrier with agglomerated large medicament particles and related method of manufacture thereof
US5951977A (en) * 1997-10-14 1999-09-14 The United States Of America, As Represented By The Secretary Of Agriculture Competitive exclusion culture for swine
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US20040062757A1 (en) * 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
CA2443935A1 (en) * 2001-04-18 2002-10-31 Merck & Co., Inc. Ppar-alpha-gamma ligands or agonists for the treatment of inflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
WO1998057631A1 (en) * 1997-06-18 1998-12-23 The General Hospital Corporation USE OF PPARη AGONISTS FOR INHIBITION OF INFLAMMATORY CYTOKINE PRODUCTION
WO2001016120A1 (en) * 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators

Also Published As

Publication number Publication date
EP1448995A1 (en) 2004-08-25
GB0127916D0 (en) 2002-01-16
ES2362494T3 (es) 2012-10-05
US7998474B2 (en) 2011-08-16
JP5362940B2 (ja) 2013-12-11
AU2002343063A1 (en) 2003-06-10
JP2005510733A (ja) 2005-04-21
ATE496302T1 (de) 2011-02-15
CA2468082A1 (en) 2003-06-05
DE60239009D1 (de) 2011-03-03
US20030133875A1 (en) 2003-07-17
WO2003046580A1 (en) 2003-06-05
CA2468082C (en) 2012-06-26
JP2013046615A (ja) 2013-03-07
EP1448995B1 (en) 2011-01-19
EP1448995B9 (en) 2011-10-12
DK1448995T3 (da) 2011-05-16

Similar Documents

Publication Publication Date Title
AU2002343063B2 (en) Assay for screening candidate drugs for the treatment of inflammatory diseases
Engevik et al. Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways
Mulders et al. Microbiota in obesity: interactions with enteroendocrine, immune and central nervous systems
Lazar et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer
Chiu et al. Protective microbiota: from localized to long-reaching co-immunity
Bashiardes et al. Non-alcoholic fatty liver and the gut microbiota
Benyacoub et al. Enterococcus faecium SF68 enhances the immune response to Giardia intestinalis in mice
Sham et al. Attaching and effacing bacterial effector NleC suppresses epithelial inflammatory responses by inhibiting NF-κB and p38 mitogen-activated protein kinase activation
Mennigen et al. Probiotic mixture VSL# 3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis
Voltan et al. Aggregating phenotype in Lactobacillus crispatus determines intestinal colonization and TLR2 and TLR4 modulation in murine colonic mucosa
Coconnier et al. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB
Hannan et al. Host–pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection
Katouli Population structure of gut Escherichia coli and its role in development of extra-intestinal infections
Rhee et al. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice
Lu et al. Lactic acid bacteria isolated from Korean kimchi activate the vitamin D receptor–autophagy signaling pathways
Inamuco et al. Sub-lethal levels of carvacrol reduce Salmonella Typhimurium motility and invasion of porcine epithelial cells
Pickard et al. Pathogen colonization resistance in the gut and its manipulation for improved health
van der Kleij et al. Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve
Mellits et al. Activation of the transcription factor NF-κB by Campylobacter jejuni
Schultz et al. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases
Juanola et al. Regulatory T cells restrict permeability to bacterial antigen translocation and preserve short‐chain fatty acids in experimental cirrhosis
Al-Mamun et al. Treatment with phenylbutyrate in a pre-clinical trial reduces diarrhea due to enteropathogenic Escherichia coli: link to cathelicidin induction
Gallois et al. Maternal milk contains antimicrobial factors that protect young rabbits from enteropathogenic Escherichia coli infection
Liu et al. Dietary supplementation of n-3 LCPUFAs prevents salmonellosis in a murine model
Jimenez et al. Quorum sensing and the gut microbiome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

Free format text: FORMER OWNER WAS: ROWETT RESEARCH INSTITUTE

PC Assignment registered

Owner name: GT BIOLOGICS LIMITED

Free format text: FORMER OWNER WAS: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

MK14 Patent ceased section 143(a) (annual fees not paid) or expired